Seeking Alpha

The FDA accepts Merck's (MRK) resubmission of a New Drug Application for its sugammadex sodium...

The FDA accepts Merck's (MRK) resubmission of a New Drug Application for its sugammadex sodium injection, which is used as a muscle relaxant during surgery. The FDA rejected the original NDA for sugammadex in 2008 and asked for additional information about allergic reactions and bleeding. (PR)
Comments (1)
  • biochemist
    , contributor
    Comments (336) | Send Message
     
    Actually sugammadex is not a muscle relaxant. It is the first selective relaxant binding agent indicated to reverse the neuromuscular blockade induced during general anaesthesia. It blocks the action of rocuronium, which is a muscle relaxant.
    7 Jan 2013, 05:18 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|